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ABSTRACT  Ionic messengers signal several critical events in carcinogenesis, including metastasis, 
the leading cause of patient mortality. The aberrant metabolic, proliferative and anti-apoptotic nature 
of neoplastic cells can be traced to the abnormal expression of their ion transporters and related 
signalling networks. In this manuscript, we discuss Na+/H+ flux, as mediated by the sodium-hydrogen 
exchanger isoform 1 (NHE1), a major ion transporter involved in tumourigenesis. Allosteric activation 
of NHE1 by external stimuli is controlled by phosphorylation of key amino acids on its cytosolic C-
terminal tail, which also acts as a signal scaffold for its regulation by intracellular protein and lipid 
binding partners. In breast cancer cells, pH homeostasis and proton dynamics are disrupted early 
in transformation. This constitutively activates NHE1, causing a reversal of the plasma membrane 
pH gradient, resulting in a more alkaline intracellular pH and a more acidic extracellular pH. NHE1-
mediated cellular alkalinization potentiates cytoskeletal remodelling, mobilizing cells for directed 
migration. Concomitant redistribution of NHE1 to invadopodia, where increased proton extrusion 
promotes proteolytic digestion of the extracellular matrix, primes cells for invasion into the blood-
stream. NHE1 hyperactivity therefore heralds an important stage in cancer cell development, criti-
cally facilitating the acquisition of the invasive phenotype necessary for metastasis to occur. The 
potential for targeting NHE1 in the development of novel chemotherapeutic applications is explored. 
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Introduction
Ionic messengers are key participants in the most fundamental 
pathways of cell communication, both within the cytoplasm and at 
the intracellular-extracellular interface. Gap junctions and diffusion 
across the plasma membrane lipid bilayer allow for the free pas-
sage of ions between cells, while membrane-bound ion channels, 
transporters, and exchangers selectively control ion traffic at the 
organellar and cellular level. The constant, asymmetrical flux of 
ions (e.g. H+, Na+, K+, Ca2+, Cl−, HCO3−) across the cell membrane 
results in an electrochemical gradient that is chiefly controlled by 
active transport. Therefore, ionic messengers can ubiquitously aid 
in metabolism as well as regulate cell volume, growth, prolifera-
tion and death in normal cells. In neoplastic cells, however, ion 
channels and their downstream signalling pathways can become 
dysregulated, thus contributing to transformation. 
Research over the last decade has confirmed that a variety of 
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ion transport proteins are expressed in cancer cells. Often, expres-
sion levels of these proteins and their perturbed functionality in 
tumour cells can be quite cancer-specific and play a significant 
role in both tumourigenesis and metastasis (Pedersen and Stock, 
2013). Changes in ion channel expression can occur at genomic, 
transcriptional, post-translational or epigenetic levels and are as-
sociated with mechanistic and signalling events that are specific 
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for the stage and type of cancer being studied. For example, the 
expression of voltage-gated Na+ channels is up-regulated in many 
types of carcinomas, while voltage-gated K+ channel expression 
may become down-regulated as cancer progresses. The subse-
quent increase in intracellular Na+ is thought to promote invasion of 
cancer cells (Fraser et al., 2014), whereas altered K+ flux can affect 
cell proliferation and migration, which aids in tumour progression 
(Fraser et al., 2014, Pardo and Stuhmer, 2014). Transformed cells 
and tumour cell lines also lose their dependency on the Ca2+ signal-
ling that drives proliferation. Indeed, the entire regulatory network 
of proteins and adaptor molecules that maintain Ca2+ signalling 
can become drastically remodelled to sustain the transformed 
phenotype (Roderick and Cook, 2008). Furthermore, in recent 
years, it has become abundantly evident that pH regulation has a 
dramatic impact on cancer progression. Therefore, the plethora of 
transporters that maintain pH homeostasis in cells have come under 
substantial scrutiny for the role they may play in cancer, from trans-
formation to metastasis. On the plasma membrane, these include: 
Na+/H+ exchangers (NHEs), monocarboxylate transporters (MCTs), 
vacuolar-type proton pump ATPases (V-ATPases), anion exchang-
ers (AEs), and bicarbonate-coupled transporters, particularly the 
Na+/HCO3− transporter (Neri and Supuran, 2011). The preceding 
review articles provide a representation of the extensive body of 
research, both in vivo and in vitro, that reiterate the importance 
of ionic messengers, their transporters, regulatory partners and 
signalling networks in cancer. However, as the complex interac-
tion between tumour cells and their immediate microenvironment 
becomes clearer, traditional roles for ion transporters are being 
redefined, sparking renewed interest in exploiting these proteins 
as potential targets in the development of novel chemotherapies. 
In the present review, we focus on one such ion transporter, the 
ubiquitously expressed Na+/H+ exchanger isoform 1 (NHE1), and 
its role and regulation in breast cancer cell development. Our aim is 
to summarize current knowledge and characterize the mechanisms 
underlying the dysregulation of NHE1 activity, a phenomenon that 
appears to drive carcinogenesis and metastasis within the tumour 
microenvironment. Finally, the potential for NHE1 as a target for 
chemotherapy is discussed.
pH homeostasis and breast cancer: the disruption of 
proton dynamics
Sodium-hydrogen exchangers (NHEs) belong to the SLC9A 
solute carrier family of ion transporters, of which there are nine 
known human isoforms (NHE1-9; SLC9A1-9). While much is known 
about the structural dynamics of NHEs (Hendus-Altenburger et al., 
2014), no precise crystal structure has been determined for any of 
the human isoforms. Human NHE1 (SLC9A1) is 815 amino acids 
in length. A topology model (Wakabayashi et al., 2000) based on 
cysteine accessibility studies, suggests that the first 500 residues are 
the hydrophobic N-terminal transmembrane domain. This domain 
is responsible for ion transport. The 315-amino acid hydrophilic 
C-terminal cytosolic domain regulates activity of the membrane 
domain and ionic homeostasis through post-translational modifi-
cations (chiefly via phosphorylation) or through interactions with 
intracellular lipid or protein binding partners (Lee et al., 2013). NHE1 
is highly sensitive to amiloride and its lipophilic derivatives, as well 
as the benzolyguanidine class of inhibitors that include cariporide 
(Donowitz et al., 2013). NHE1 does not require energetic input 
from ATP hydrolysis, instead it uses the energy of the inwardly 
directed sodium gradient to extrude protons. However, NHE1 is an 
ATP-binding transporter dependent on cellular ATP for its activa-
tion (Shimada-Shimizu et al., 2013). NHE1 extrudes intracellular 
H+, a by-product of metabolism or electrochemical transport, in 
an electroneutral 1:1 ratio in exchange for extracellular Na+. The 
directionality of Na+/H+ exchange is reversible and dependent on 
the transmembrane concentration gradients for both ions, as well as 
intracellular pH (pHi). Increased intracellular H+ ions rapidly stimulate 
exchanger activity (Wakabayashi et al., 1997b). Na+/H+ exchange 
results in cellular alkalinizition that simultaneously maintains both 
pHi and cell volume. Hence, dysregulation of Na+/H+ exchange can 
have significant deleterious effects on cells. Indeed, many NHE 
isoforms can contribute to the pathophysiology of various human 
diseases including cancer (Fuster and Alexander, 2014). 
It has long been known that the solid tumor cores acidify their 
cores (Hasuda et al., 1994). Poor vascularization of tumours may 
account for some of the extracellular acidification. However, this 
phenomenon can be distinguished from the elevation of pHi in vari-
ous types of tumour cells that has, at least in some cell types, been 
shown to be due to an increase in Na+/H+ exchanger activity, even 
in cultures of monolayers of cells (Karki et al., 2011). Elevated pHi 
and acidification of extracellular space is reliant on the regulation 
of the Na+/H+ exchanger (Amith and Fliegel, 2013).
For breast cancer cells, when tested in vitro, highly invasive 
MDA-MB-231 cells were found to actively acidify their non-buffered 
balanced salt solution media in culture. This did not occur with 
estrogen receptor (ER)-positive, lowly invasive MCF-7 breast 
cancer cells, or normal mammary epithelial cells. This finding was 
particularly significant since MDA-MB-231 cells are representative 
of the metastatic triple-negative form of breast cancer (negative 
for the expression of estrogen (ER) and progesterone receptors 
(PR), and human epidermal growth factor receptor 2, HER2). The 
same study also found that metastatic breast tumour cells from 
pleural effusions were 200-fold more active in acidifying their 
extracellular culture media compared to non-malignant mam-
mary cells, suggesting that extracellular acidification also occurs 
in tumours in vivo (Montcourrier et al., 1997). In E7 oncogene-
induced transformation of NIH3T3 murine fibroblasts and human 
keratinocytes, early cytoplasmic alkalinization was a direct result 
of an increase in NHE1 activity. This increase was driven by an 
underlying increase in the exchanger’s affinity for allosteric proton 
binding. Interestingly, the reprogramming of cellular metabolism 
to aerobic glycolysis was found to be a result of, and dependent 
upon, E7 oncogene-mediated alkalinization. Furthermore, in the 
presence of the NHE1 inhibitor 5-(N,N-dimethyl) amiloride, or 
when pHi was clamped to non-tumorigenic levels, cells did not 
exhibit the transformed phenotype, and no subsequent increased 
growth rate, serum- and anchorage-independent growth, glycolytic 
metabolism or in vivo tumour development in nude mice was ob-
served (Reshkin et al., 2000b). The continued rise in intracellular 
pH as the tumour progresses is associated with elevated aerobic 
glycolysis, the so-called “Warburg effect” (Vander Heiden et al., 
2009), metabolic reprogramming of pyruvate oxidation to lactic 
acid conversion, and extracellular oxygen and nutrient depletion 
as a result of poor perfusion (Parks et al., 2013, Webb et al., 2011).
The activation of NHE1 leads to a reversal of the pH gradient of 
tumour cells early in oncogenic transformation. The H+ ions extruded 
chiefly by NHE1 build up in the interstitial spaces between cells of 
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the developing tumour; this acidifies the tumour microenvironment 
and facilitates metastasis. The resultant low pH is necessary for 
the optimal activity of matrix metalloproteinases and other proteo-
lytic enzymes that degrade the extracellular matrix, and aid in the 
detachment and dissemination of tumour cells. Coupled with poor 
vasculature, nutrient deprivation, and hypoxic conditions in and 
around growing tumours, the acidic microenvironment promotes 
cancer cell survival, proliferation, migration, invasion and eventual 
metastasis to sites distant from the primary tumour (Cardone et 
al., 2005b, Donowitz et al., 2013). 
The C-terminal domain of NHE1: a tail of complex 
regulation
The functional regulation of NHE1 activity in normal cells is both 
complex and myriad. Apart from the allosteric activation of NHE1 
by intracellular protons, several external factors are also known to 
drive exchanger activity, including: growth factors and hormones in 
serum, and several classes of receptors on the plasma membrane 
(receptor tyrosine kinases, G-protein coupled receptors, and integrin 
receptors). Modulation of NHE1 activity by external factors is medi-
ated through its cytosolic C-terminal tail, either via phosphorylation 
of specific amino acids, binding of interacting adaptor proteins or 
lipids, or conformational changes, all of which potentially alter the 
affinity of the exchanger’s allosteric binding site for H+ (Putney 
et al., 2002). Early studies showed that, in physiological condi-
tions, the activation of NHE1 by growth factors (like a-thrombin 
and insulin) is due to an increase in the allosteric affinity of the 
exchanger for internal H+ (Paris and Pouysségur, 1984). While 
the transmembrane domain of NHEs is highly conserved amongst 
the isoforms, the C-terminal domain is not. In NHE1, deleting the 
C-terminal tail does not impact ion exchange but does affect H+ 
“sensing”, a measure of activity at a particular pHi. In support of 
this proton-sensing model, one study examined four subdomains of 
the cytosolic tail of NHE1 in the unstimulated state: I, amino acids 
(aa) 516-590/595; II, aa 596-635; III, aa 636-659; and IV, aa 660-
815. Truncations of these amino acid sequences suggested that 
subdomain I plays an important role in the maintenance of high 
pHi sensitivity of the exchanger, while subdomains II and IV were 
shown to have no discernible role in pH sensing. Subdomain III is 
involved in autoinhibition of NHE1, which is facilitated by calmodulin 
binding and, potentially, the spatial arrangement of subdomain II, 
a proposed “flexible loop” domain that aids this interaction (Ikeda 
et al., 1997) (Fig. 1).
Several major regulatory phosphorylation events on the NHE1 
tail have been mapped to the region between aa 636 to 815 
(Wakabayashi et al., 1994). These include target residues for 
phosphorylation by: extracellular signal-regulated kinase (ERK1/2) 
(Liu et al., 2004), mitogen-activated protein kinase (MAPK) (Malo 
et al., 2007)], and B-Raf kinase (Karki et al., 2011); see Hendus-
Altenburger et al., (2014) for a comprehensive listing. However, 
not all the protein kinases and phosphatases that phosphorylate 
NHE1 have been identified. Similarly, several kinases are known 
to mediate NHE1 activity, but their exact amino acid targets are yet 
to be determined. Based on the relative positions of these known 
and predicted phosphorylation sites on the NHE1 C-terminal tail, 
it has been intriguingly suggested that phosphorylation at these 
sites may be interdependent, forming “clusters” of phosphorylation 
events that could be involved in the temporal regulation of NHE1 
(Hendus-Altenburger et al., 2014). Recently, it was demonstrated 
that phosphorylation can induce structural changes in the C-terminal 
of NHE1 that mediate phosphorylation-induced regulation (Li et 
al., 2013a). To date, however, it is unclear if these same regula-
tory phosphorylation sites and mechanisms are retained in breast 
cancer cells (Amith and Fliegel, 2013). 
Of particular interest is Ser703, where activation of the ex-
changer is attributed to phosphorylation by p90 ribosomal S6 
kinase (p90RSK), a downstream kinase of ERK1/2. Site-specific 
mutation of Ser703 to a non-phosphorylatable alanine residue, 
did not affect acid-stimulated Na+/H+ exchange but completely 
prevented the increase in H+ affinity of NHE1 usually associated 
with growth-factor stimulation (Takahashi et al., 1999). Later, a novel 
Fig. 1. The mammalian Na+/H+ exchanger, NHE1 
(SLC9A1). The widely accepted structural model of 
NHE1 describes a plasma transmembrane domain 
with 12 segments, and a cytosolic C-terminal domain 
that regulates Na+/H+ exchange. The C-terminal domain 
is further divided into four sub-domains 
characterized according to their interac-
tions with intracellular protein and lipid 
binding partners and sites of phosphory-
lation. Basal NHE1 activity in normal 
(non-tumour) cells maintains intracellu-
lar pH between 6.9-7.1 and extracellular 
pH between 7.2-7.4. Akt, protein kinase 
B; CaM, calmodulin; CAII, carbonic an-
hydrase II; CHP, calcineurin homologous 
protein; E, ezrin; Erk1/2, Extracellular 
signal-regulated protein kinases 1 and 
2; R, radixin; M, moesin; p38MAPK, 
p38 mitogen-activated protein kinases; 
P, protein phosphorylation site; PIP2, 
phosphatidylinositol 4,5-bisphosphate; 
p90rsk, ribosomal s6 kinase or MAPK-
activated protein kinase-1.
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association of 14-3-3b with NHE1 at Ser703 in response to serum 
stimulation was demonstrated (Lehoux et al., 2001). 14-3-3 binding 
to Ser703 in its phosphorylated state was necessary for serum-
induced exchanger activity, and prevented its dephosphorylation. 
Mitogen-activated protein kinase kinase (MEK) inhibitors prevent 
14-3-3 binding to NHE1 in serum-stimulated conditions, which 
has broader implications on MEK-ERK-RSK-mediated regula-
tion of exchanger activity (Lehoux et al., 2001) and, conversely, 
on the NHE1-mediated activation of MAPK signalling pathways 
(Pedersen et al., 2007). In cancer cells in vivo, low serum is the 
norm in the tumour microenvironment, yet exchanger activity is 
unaffected. This is particularly evident in breast cancer cells where 
NHE1 becomes overactive with serum depletion. Exactly how the 
regulatory mechanisms underlying NHE1 activity is altered in low 
serum is not fully understood (see also below) but the activation 
of NHE1 in the low serum environment suggests that Ser703 is 
not the only regulator of NHE1. Two phosphorylatable residues 
upstream of Ser703 are Ser726 and Ser729. Substitution of Ser726 
and Ser729 on NHE1 with alanine in non-tumour cells protected 
against cell death induced by serum deprivation, and prevented 
cellular alkalinization associated with apoptosis in a p38MAPK-
dependent manner. Conversely, substituting these serines for 
phospho-mimetic glutamic acids resulted in a more alkaline basal 
pHi and increased susceptibility to cell death signals (Grenier et 
al., 2008). These studies allude to how tight the regulation over 
phosphorylation events on the NHE1 C-terminal can be, even at 
a single amino acid residue. Testing these mutations in a breast 
cancer cell model would therefore further elucidate the regulation 
of NHE1 in low serum conditions, and define exactly how much 
cell survival depends on Na+/H+ exchange. 
Independent of phosphorylation by protein kinases and phos-
phatases, NHE1 interaction with its cofactors and binding partners 
is also important in its regulation, particularly in response to cell 
stressors and external stimuli. NHE1 is regulated by a multitude 
of binding proteins (reviewed in (Fliegel, 2009)). Several aspects 
of this regulation are of particular interest in breast cancer and in 
relation to the tumour microenvironment. NHE1 is proposed to be 
a scaffolding protein, an idea that stemmed from the discovery that 
it directly associates with the actin binding proteins ezrin, radixin 
and moesin (ERM) in the lamellipodia of fibroblasts, where NHE1 
is predominantly localized (Baumgartner et al., 2004). Mutations 
in the exchanger that disrupt binding of ERM proteins resulted in 
irregular cell shape with disorganization of focal adhesion assembly 
and actin stress fibers. While these mutations disrupted the corti-
cal cytoskeleton of fibroblasts, no impairment of Na+/H+ exchange 
activity was observed (Denker et al., 2000). NHE1-ERM interaction 
is also involved in cell survival signaling (Wu et al., 2004). Death 
domain-associated protein Daxx stimulates exchanger activity 
under ischemic stress, and competes with ezrin in binding to NHE1 
(Jung et al., 2008). 
Additional hormone-induced regulation of NHE1 is mediated 
through the lipid-interacting domain of the C-terminal tail proximal 
to the transmembrane domain. This region spans aa 542 to 598 
and associates with acidic phospholipids (e.g. phosphatidylino-
sitol-4,5-biphosphate, PIP2) and other hydrophobic residues, 
as well as the ERM proteins and Daxx, in a competitive manner 
(Hendus-Altenburger et al., 2014). Diacylglycerol, a by-product of 
PIP2 hydrolysis mediated by hormone-induced G protein-coupled 
receptor activation, and tumour-promoting phorbol esters, are 
potent activators of protein kinase C (PKC). PKC is thought to be 
involved in the hormonal activation of NHE1, but is not known to 
phosphorylate the exchanger. Instead, it is proposed that diacylglyc-
erol and phorbol esters bind directly to the lipid interacting domain, 
inducing conformational changes in this region by increasing its 
association with membrane lipids (Shimada-Shimizu et al., 2014, 
Wakabayashi et al., 2010). 
As previously mentioned, calmodulin (CaM), a Ca2+-binding 
protein that regulates NHE1-mediated Ca2+ signalling, is an impor-
tant protein interacting with NHE1. CaM binds to two neighbouring 
sites on the C-terminal tail of NHE1: one high affinity site at aa 
636-656, and a second intermediate affinity at aa 657-700 (Ber-
trand et al., 1994). Deletion of this region induces a constitutively 
active NHE1, a shift in sensitivity towards alkaline pHi, and a loss 
of exchanger responsiveness to increases in intracellular Ca2+ 
concentration [Ca2+]i (Wakabayashi et al., 1997a). In quiescent 
cells, with low [Ca2+]i and reduced CaM binding, this portion of the 
tail has an autoinhibitory effect on exchanger activity. Increases 
in [Ca2+]i elicit CaM binding to the high affinity site on the NHE1 
C-terminal tail. CaM binding is thought to weaken the association 
of the autoinhibitory domain with or near the H+-modifier site on 
the transmembrane domain, thereby allowing H+ to bind to and 
up-regulate the activity of the exchanger (Koster et al., 2011) and 
CaM binding to NHE1 has recently been demonstrated in vivo 
(Li et al., 2013b). However, it is unclear if CaM binding to NHE1 
in breast cancer cells results in similar elevation of NHE1 activity 
under physiological conditions. 
NHE1 regulation by second messenger Ca2+ signalling also oc-
curs through its interaction with calcineurin B homologous proteins 
1 and 2 (CHP1, CHP2) and tescalcin (also known as CHP3), which 
bind to the juxtamembrane region of the C-terminal tail. CHP1 bind-
ing to NHE1 increases its localization to the plasma membrane, 
and aids in antiporter activity by stabilizing the exchanger at the cell 
surface. Mutations to the CHP1 binding site of NHE1 do not prevent 
it from anchoring at the cell membrane, but do reduce the half-life 
of NHE1. This may be due to an unstable conformation that also 
negatively impacts NHE1 activity (Matsushita et al., 2011). Similarly, 
CHP3 (tescalcin) binding to NHE1 also increases exchanger ex-
pression and half-life at the plasma membrane, likely by enhancing 
its biosynthetic maturation (Zaun et al., 2008). Conversely, CHP2, 
which has ~60% amino acid sequence homology to CHP1, interacts 
more strongly with NHE1, but is found in much lower levels in the 
cytosol than CHP1. However, tumour cells express elevated CHP2 
levels. In non-tumour cells co-expressing either CHP1 or CHP2 
bound to NHE1, cytosolic pH was high (7.4-7.5) independent of 
serum in CHP2-NHE1 cells. In the CHP1-NHE1 cells, cellular 
alkalinization was only observed cells in the presence of serum. 
This indicated that CHP2 constitutively activated NHE1. In fact, 
CHP2-NHE1 cells were still viable after 7 days of serum deprivation 
while CHP1-NHE1 cells were not, suggesting that CHP2 aids in 
the maintenance of an alkaline pHi. In this respect, CHP2-NHE1 
cells were similar to malignantly transformed cells, indicating that 
NHE1-mediated cellular alkalinization under the regulation of CHP2 
may be protective in nutrient-depleted conditions that mimic those 
of the tumour microenvironment (Pang et al., 2002). 
At the distal end of the C-terminal, NHE1 associates with cyto-
solic carbonic anhydrase isoform II (CAII) (Li et al., 2006). Carbonic 
anhydrases are a class of enzymes that catalyze the hydration of 
CO2 into HCO3− and H+, and are involved in respiration, acid-base 
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regulation, and electrolyte secretion (Neri and Supuran, 2011). CAII 
is required for the efficient exchange of Cl−/HCO3− by the red blood 
cell anion exchanger AE1 (Motais et al., 1975, Sly and Hu, 1995). 
CAII binds directly to both AE1 (Vince and Reithmeier, 1998) and 
NHE1 (Li et al., 2002). In NHE1, site-specific mutagenesis revealed 
that the critical amino acids involved in CAII binding are Ser796 
and Asp797 (Li et al., 2006). This association is thought to enhance 
the efficacy of proton extrusion. In many tumour cells, however, it 
is the overexpression of the transmembrane isozymes of carbonic 
anhydrase, CAIX and CAVII, which is related to poor prognosis and 
response to therapy (Neri and Supuran, 2011). CAIX and CAVII 
are also involved in the regulation of cellular pH homeostasis, and 
the pH of the tumour microenvironment, primarily via bicarbonate 
ion exchange (Meijer et al., 2014). Could there be an association 
between the IX and VII isozymes of carbonic anhydrase and NHE1 
at the plasma membrane of breast cancer cells, where pH regulation 
is so important to cancer progression? The prospect is intriguing 
given that CAIX overexpression is detected in the immunohisto-
chemical analysis over 40% of ER-PR-positive/HER2-negative and 
over 80% ER-PR-negative/HER2-positive primary human breast 
tumours (Kaya et al., 2012). Tissue microarray data from patients 
with various clinical subtypes of triple-negative breast cancer also 
showed a similar high expression of CAIX (Jeon et al., 2013). De-
spite these observations, however, a direct association between 
NHE1 and CAIX has not been reported. As illustrated in Fig. 1, it 
is evident that piecing together the complex puzzle of signalling 
events and cofactor associations regulating NHE1 activity and ion 
exchange is hugely pertinent to both transformation and the latter 
stages of cancer cell development, as well as the establishment 
of the tumour microenvironment that mediates metastasis.
Na+/H+ exchange in the tumour microenvironment: 
triggering metastasis 
Growth factor and nutrient-enriched serum activates NHE1 
in normal cells while, paradoxically, serum deprivation activates 
NHE1 activity in cancer cells. This phenomenon becomes more 
pronounced in the latter stages of tumourigenesis. MCF-10A cells 
are a highly differentiated, non-tumorigenic human mammary 
epithelial cell line, while MCF-7 are minimally tumorigenic, lowly 
differentiated breast cancer cells. When comparing MCF-10A to 
MCF-7 cells, it was found that serum deprivation inhibited NHE1 
activity in MCF-10A cells but increased exchanger activity in MCF-
7 cells. This increase in NHE1 activity was due to an increase in 
the affinity of the internal H+ regulatory site of the exchanger, and 
not due to changes in Na+ kinetics or NHE1 protein expression 
(Reshkin et al., 2000a). This effect also occurred in highly invasive 
and metastatic MDA-MB-435 cells; however, it was later determined 
that this is a melanoma cell line rather than a breast cancer cell 
line (Ellison et al., 2002). We recently confirmed these results in 
MCF-7 cells, and further demonstrated that serum deprivation 
increases NHE1 activity in metastatic triple-negative, moderately 
invasive MDA-MB-468 cells, and in aggressively invasive MDA-
MB-231 breast cancer cells (Amith et al., 2015). Given that cancer 
cells survive and thrive in the low-serum conditions of the tumour 
microenvironment, these findings are unsurprising. In fact, despite 
the aberrant expression of growth factors, their receptors, and 
signalling pathways associated with the transformed phenotype, 
cell effector functions such as motility and invasiveness are neither 
negated nor limited by nutrient depletion, low oxygen and low 
pH. Instead, these conditions actually confer increased migratory 
and invasive capacity to breast cancer cells as they metastasize, 
characteristics thought to be potentiated by constitutively high 
NHE1 activity. 
The mechanisms by which NHE1 activity is up-regulated in 
serum-deprived conditions are slowly coming to light. As noted 
above, CHP2 bound to NHE1 notably increased intracellular al-
kalinization and conferred a malignantly transformed phenotype 
to non-tumour cells (Pang et al., 2002). Another possibly critical 
pathway is the RhoA/p160ROCK/p38MAPK signalling cascade 
(Cardone et al., 2005a). In MCF-7 and MDA-MB-231 breast can-
cer cells, low serum activates NHE1 through a sequential RhoA/
p160ROCK/p38MAPK signalling cascade gated by direct protein 
kinase A (PKA)-mediated phosphorylation of RhoA at Ser188, a 
key residue that blocks RhoA activation. 
Serum deprivation also initiates a dynamic remodelling of 
the tumour cell cytoskeleton, priming it for directed migration. In 
migrating MCF-7 and MDA-MB-231 cells, there is a redistribution 
of NHE1, RhoA, and phospho-RhoA to the leading-edge compart-
ments of pseudopodia (Cardone et al., 2005a). Invadopodia are 
discrete extensions of invasive and metastatic tumour cells. In 
malignant MDA-MB-231 cells, NHE1 was also present in invado-
podia. In these structures, NHE1 expression was associated with: 
well-defined areas of acidification in peri-invadopodial spaces; and 
focal regions of proteolytic extracellular matrix (ECM) degrada-
tion, as shown by co-localization of NHE1 with the invadopodial 
marker, cortactin (Busco et al., 2010). Cortactin phosphorylation, 
an important precursor of invadopodia formation, was necessary 
for the recruitment of NHE1 to primary invadopodial structures 
(Magalhaes et al., 2011). 
As established above, the high rate of H+ extrusion at the inva-
dopodia of tumour cells creates areas of acidic pH that facilitates 
proteolytic digestion of the ECM. The serine proteases and matrix 
metalloproteinases (MMPs) required for ECM degradation at the 
invadopodia of breast cancer cells need the acid conditions estab-
lished by NHE1 for optimal enzymatic activity (Fig. 2) (Greco et al., 
2014). In addition to facilitating the dissociation of cells from the 
ECM, extruded protons also promote cell-matrix interaction and 
adhesion at the cell front, mediated by ECM integrins, selectins 
and cadherins. Together, these processes culminate in migration 
of the tumour cell along the ECM (focal adhesion), and extravasa-
tion and invasion of cells through the ECM (focal digestion) into 
blood vessels where they are able to metastasize elsewhere in 
the body (Stock et al., 2008). 
Because of its critical role in proton extrusion, NHE1 must be 
tightly controlled by cell surface interacting partners, underlying 
signalling events, and associations with intracellular adaptor mol-
ecules. These all work in concert to form the NHE1 interactome 
that predicates cancer cell development. The invadopodial-ECM 
interface is therefore a hub of intricate physiological processes, 
mediated either directly or indirectly by NHE1 activity, that critically 
determine whether or not breast cancer cells acquire the invasive 
phenotype necessary for metastasis. Notably, these morphological 
changes are typical of epithelial-mesenchymal transition (EMT), an 
evolutionarily conserved developmental process by which tumour 
cells become invasive. In EMT, tumour cells undergo simultaneous 
molecular changes, typically: loss of epithelial marker, E-cadherin; 
and gain of mesenchymal markers, N-cadherin and vimentin 
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(Cheung and Ewald, 2014). Currently, there is no evidence linking 
NHE1 to the molecular mechanisms controlling EMT; research delv-
ing into this area could therefore be both provocative and promising. 
Na+/H+ exchanger interactions with other transporters
Further mechanistic insights into the underlying network of pH 
regulation in tumour cells and their immediate microenvironment can 
also be gained by examining the interactions between NHE1 and 
other ion transporters. Here we examine four other ion transporters, 
voltage-gated sodium channels, V-ATPases, anion exchangers 
and bicarbonate transporters. Voltage-gated sodium channels 
are integral membrane proteins. Each channel consists of a large 
a-subunit and one or two auxiliary b-subunit. The a-subunit forms 
the sodium selective transporting pore. Nine isoforms of the sodium 
transporting a-subunit have been identified in higher vertebrates: 
NaV1.1 - 1.9, reviewed in (Goldin, 2001). Interestingly, it is mainly 
the neonatal splice variant of NaV1.5 (nNaV1.5) that human breast 
cancer cells express both in vitro and in vivo (Brackenbury et al., 
2007, Fraser et al., 2005, Fraser et al., 2003, Onkal and Djamgoz, 
2009), and nNaV1.5 expression is suggested to be an integral part 
of the overall cancer process (Onkal and Djamgoz, 2009). NaV1.5 
is highly expressed in MDA-MB-231 breast cancer cells, less so in 
minimally tumourigenic MCF-7 cells, and not at all in non-tumour 
MCF-10A mammary epithelial cells. Specific inhibitors of NaV1.5 
(tetradotoxin, TTX) and NHE1 (5-(N-ethyl-N-isopropyl)-amiloride, 
EIPA) both reduce H+ efflux in triple-negative, highly invasive MDA-
MB-231 cells, TTX by ~25% and EIPA by ~90%. TTX and EIPA also 
inhibited cell invasiveness and extracellular gelatinolysis (a measure 
of ECM digestive capability) in MDA-MB-231 cells. However, neither 
inhibitor affects H+ efflux in hormone receptor-positive, lowly invasive 
MCF-7 cells. NaV1.5 also co-localizes with NHE1 in caveolae (Fig. 
2), likely forming a complex that enhances NHE1-mediated acid 
extrusion and facilitates ECM degradation (Brisson et al., 2011). 
Additionally, NaV1.5 is expressed in a complex with NHE1 in the 
focal areas of ECM digestion around invadopodia (Fig. 2). NaV1.5 
activity increased Src kinase activity and cortactin phosphoryla-
tion, modifying the F-actin polymerization that ultimately results in 
cell polarization and cytoskeletal rearrangement towards a more 
invasive morphology (Brisson et al., 2013). These studies suggest 
that NaV1.5 is important in tumourigenesis in breast cancer cells 
and is in association with NHE1. 
V-ATPases are multi-subunit membrane proteins localized in sev-
eral intracellular compartments and on the plasma membrane. They 
translocate protons across cells and are overexpressed in tumour 
cells. HCO3−-coupled transporters include Na+/HCO3− co-transport-
ers (NBCn1) and Cl−/HCO3− exchangers reviewed in (Gorbatenko 
et al., 2014)). Specific inhibitors of V-ATPases (bafilomycin) and 
anion exchangers (4,4(-diisothiocyanato-stilbene-2,2--disulphonic 
acid, which also negates the involvement of bicarbonate transport 
via AEs), did not affect H+ flux in MDA-MB-231 cells, indicating that 
proton extrusion is largely due to NHE1 and NaV1.5, albeit to varying 
degrees (Brisson et al., 2011). MCF-7 cells are ERa-positive, but 
are negative for the expression of HER2 (also known as ErbB2), 
a receptor tyrosine kinase expressed in about 30% of metastatic 
breast tumours. N-terminal truncation of ErbB2 (NErbB2), renders 
Fig. 2. Proton extrusion in the tu-
mour microenvironment. On the 
plasma membrane of tumour cells, 
NHE1 works in concert with other 
ion transporters (monocarboxylate 
transporters, vacuolar-type proton 
pump ATPases, anion exchang-
ers, and bicarbonate-coupled 
transporters, including the Na+/
HCO3
− transporter [NBCn1]) to 
facilitate directed migration and 
extracellular matrix degradation by 
serine proteases and matrix metal-
loproteinases. In caveolae and in-
vadopodia, NHE1 co-localizes with 
voltage-gated sodium channels 
(NaV1.5) to prime cells for invasion 
and metastasis. However, NHE1 is 
the major promoter of proton extru-
sion in the peri-invadopodial tumour 
microenvironment at the leading 
edges of invasive cells. AE, anion 
exchangers; Lac, lactate; MCT, 
monocarboxylate transporters; 
V-ATPases, vacuolar-type proton 
pump ATPases; VGSC, voltage-
gated sodium channels.
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it constitutively active. In MCF-7 cells, expression of ErbB2 causes 
an up-regulation of NBCn1 at both the mRNA and protein levels 
that is not seen with NHE1. However, knockdown and chemical 
inhibition assays demonstrated that both transporters are involved 
in H+ extrusion. Interestingly, NHE1 was more localized to lamelli-
podia in NErbB2-MCF7 cells, while NBCn1 localized predominantly 
at cell-cell contacts on the plasma membrane, shifting cell shape 
from an epithelial to a more fibroblast-like morphology (Lauritzen 
et al., 2010). Na+/HCO3− transport and its role in enhancing acid 
extrusion are also thought to be important in primary human breast 
carcinomas. 
Ion transporter expression levels and cancer
ONCOMINE™ (www.oncomine.org) is a freely accessible cancer 
microarray database and web-based data-mining platform used 
to evaluate genome-wide expression analyses (Rhodes et al., 
2004). We used the ONCOMINE™ database to compare changes 
in mRNA expression of NHE1 (SLC9A1), NaV1.5 (SCN5A), and 
NBCn1 (SLC4A7) in cancerous versus normal tissue. As seen in 
Fig. 3, there is at least a two-fold increase in NHE1 mRNA expres-
mentioned that the data obtained from the ONCOMINE™ analysis 
are not from microdissected tissues, so adipocytes and other cell 
types are also present within the tissue. Nonetheless, these data 
are supportive of and reiterate the importance of NHE1 expression 
in various primary human carcinomas, and potentially in cancers 
of the breast. 
Inhibiting NHE1: implications for breast cancer 
chemotherapy
Carcinogenesis is a dynamic process, so breast cancer manifests 
as a heterogeneous disease that clinically presents as a complexity 
of different cellular subtypes, based on the expression of: estro-
gen receptors (ERs), progesterone receptors (PRs), and human 
epidermal growth factor receptor-2 (HER2). In the broadest sense, 
breast cancer can be classed as: ER-positive, HER2-positive, and 
triple-negative (lacking ER, PR and HER2 expression). The major-
ity of breast cancers are either ER-positive (~75%) or PR-positive 
(~55%), while HER2 expression is up-regulated in the tumour cells 
of ~20-30% of patients with the disease. Several targeted therapies 
for ER/PR-positive and HER2-positive cancers are known. How-
Fig. 3. Fold changes in mRNA expression of NHE1 
[SLC9A1], NBCn1 [SLC4A7] and NaV1.5 [SCN5A] in 
various cancers relative to normal tissue. ONCOMINE 
(www.oncomine.org) (Rhodes et al., 2004) database 
analysis of various primary human cancers showing: 
(A) NHE1; (B) NBCn1; and (C) NaV1.5 mRNA expres-
sion compared to normal tissues (P<0.05). Trial sizes 
and study references are detailed in Supplementary 
Tables 1-3. (A) Dark symbols indicate studies that were 
statistically significant at (P<0.05). Lighter symbols are 
studies that were not significant. Dark lines indicate mean 
of statistically significant studies. Lighter line indicates 
mean of non-significant studies.
sion in cancers in the breast, cervix, lungs, ovaries, 
pancreas, prostate and blood, while a three-fold 
or more increase in observed in bladder, esopha-
geal, or renal cancer tissues (Fig. 3A, P<0.05). 
NBCn1 shows a 1.5-fold increase or greater in 
mRNA expression in brain, colorectal, gastric, liver, 
leukemic and pancreatic carcinomas, as well as 
in lymphomas (Fig. 3B, P<0.05). NaV1.5 mRNA 
expression increases two-fold in lung carcinoma, 
whereas in breast cancers, the increase in expres-
sion is only one-fold (Fig. 3C, P<0.05). When we 
specifically examined the various clinical subtypes 
of breast carcinomas, a clearer picture of the 
expression of these transporters emerged. NHE1 
expression increases at least 1.5-fold in invasive 
breast cancers, particularly those of lobular origin 
(Fig. 4A, P<0.05, Supplementary Table 1). NBCn1 
expression appears to increase in invasive breast 
cancers, but due to the small sample size (either 
of normal or cancer tissue) used in these studies, 
this result will require further validation (Fig. 4B, 
Supplementary Table 2). Drawing conclusions 
from the data for changes in NaV1.5 expression 
in breast carcinomas (Fig. 4C, Supplementary 
Table 3) are similarly inconclusive. It should be B C
A
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ever, hormone and HER2-targeted therapy is ineffective against 
triple-negative breast cancer (TNBC), which accounts for ~15% 
of breast cancers and often presents as highly aggressive with 
poor prognoses for patient survival (Cadoo et al., 2013). Cytotoxic 
chemotherapy is standard in combatting TNBC, both at early and 
latter stages of the disease. Several classes of chemotherapy 
agents have been used in TNBC treatment to varying degrees of 
success. These include: platinum agents (e.g. cisplatin); taxanes 
(e.g. paclitaxel); and anthracyclines (e.g. doxorubicin) (Isakoff, 
2010). Unfortunately, the development of a multidrug resistant 
phenotype often occurs during the course of chemotherapy, ren-
dering it less effective (Martin et al., 2014). 
Evidence suggests that the acidic extracellular tumour microen-
vironment that is established by the constitutive activation of NHE1, 
actively promotes cancer progression. Also, the manipulation of 
intracellular or, in particular, the extracellular pH of tumour cells 
may aid cancer treatment strategies, possibly in combinatorial 
approaches to therapy (Harguindey et al., 2013, McCarty and 
Whitaker, 2010). This may occur because chemotherapeutic 
agents are mildly basic and the acidic tumour microenvironment 
may partially neutralize their efficacy and actually contribute to 
effective chemotherapy strategy in patients with metastatic dis-
ease (Donowitz et al., 2013). Clinical trials involving drugs that 
can inhibit NHE1 activity such as cariporide (Avkiran et al., 2008), 
have been in the area of treatment for ischemic-reperfusion injury. 
Unfortunately, adverse effects associated with the use of cariporide 
outweighed its cardioprotective benefits. These off-target effects 
may have been due to the dose used and method of administration 
(Karmazyn, 2013). Future clinical trials in cancer patients need to 
address issues of dosage and cytotoxicity to minimize adverse 
effects and maximize drug benefits. A first step could be to target 
NHE1 in combination with adjuvant (administered post-surgery) 
or neoadjuvant (administered prior to surgery) chemotherapies, 
which could potentially be beneficial no matter what type of 
cancer is being treated, since NHE1 may be up-regulated in a 
multitude of carcinomas (Fig. 3A). Drug penetration of tumours 
is also an important aspect of chemotherapy (Minchinton and 
Tannock, 2006). At there present time however, it is not known 
whether NHE1 inhibitors themselves penetrate acidic core tumor 
environments, so further studies are needed in this area. Regret-
tably, there is also a dearth of studies exploring the use of NHE1 
inhibitors themselves in treating metastasis and in combination 
Fig. 4. Fold changes in mRNA expression of NHE1 [SLC9A1], 
NBCn1 [SLC4A7] and NaV1.5 [SCN5A] in breast cancer 
subtypes relative to normal breast tissue. ONCOMINE 
database analysis of various primary human breast cancers 
showing: (A) NHE1; (B) NBCn1; and (C) NaV1.5 mRNA expres-
sion compared to normal breast tissues (P<0.05). Trial sizes 
and study references are detailed in Supplementary Tables 
1-3. (A) Dark symbols indicate studies that were statistically 
significant at (P<0.05). Lighter symbols are studies that were 
not significant. Dark lines indicate mean of statistically signifi-
cant studies. Lighter line indicates mean of non-significant 
studies. Asterisk (*) indicates studies with small sample sizes 
of normal or cancer tissues (n<10).
B C
Achemotherapy resistance. Additionally, weakly basic agents may become protonated in low pH, whereby 
they are unable to permeate into the cell to reach their 
molecular targets (Webb et al., 2011). Several studies 
have supported this suggestion. Xenograft tumours of 
MCF-7 cells, representative of ER-positive tumours, 
were more susceptible to doxorubicin in vivo at an 
extracellular pH of 7.4 versus 6.8 (Raghunand et al., 
1999). Lower extracellular pH also induced greater 
migration and higher resistance to paclitaxel and doxo-
rubicin in MCF-7 cells. However, when bioenergetics 
modulators (e.g. glycolysis inhibitors), were used to 
pretreat cells, an increased sensitivity to paclitaxel 
and doxorubicin was observed (Tavares-Valente et al., 
2013). In a recent study, we knocked out NHE1 from 
aggressively tumorigenic triple-negative MDA-MB-231 
cells. This dramatically decreased the ability of these 
cells to form subcutaneous xenograft tumours in athymic 
nude mice. In vitro, NHE1-knockout MDA-MB-231 cells 
were also markedly more sensitive to paclitaxel (Amith 
et al., 2015). To date, however, despite the significant 
body of evidence supporting the role of NHE1 in breast 
cancer carcinogenesis from neoplastic transformation 
to metastasis, there is little direct evidence to confirm 
that pharmacological inhibition of NHE1 would be an 
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with chemotherapies. We recently showed that pretreating MDA-
MB-231 and MDA-MB-468 breast cancer cells (representative 
of two different clinical subtypes of TNBCs) with NHE1 inhibitors 
increases their susceptibility to low-dose paclitaxel-mediated cell 
death, and decreases their metastatic potential in vitro. This was 
especially true in serum-depleted conditions that mimic those of 
the tumour microenvironment (Amith et al., 2015). These findings 
indicate that there is merit to the hypothesis that NHE1 inhibitors 
could be used as co-adjuvants to chemotherapy; further testing 
in other breast cancer subtypes is worth pursuing. 
Summary
The pivotal role that ionic messengers play in carcinogenesis 
is evident, but it is disrupted proton dynamics and the subse-
quent dysregulation of pH homeostasis that is associated with 
the evolution of cancer from neoplasia to metastasis. Oncogenic 
transformation initiates the NHE1-driven cellular alkalinization that 
facilitates glycolytic metabolism and promotes cancer cell survival 
in the hypoxic and nutrient-depleted tumour microenvironment. 
NHE1 relocalizes to the leading edges of migratory cells and in-
vadopodia of invading cells, where its activity facilitates the onset 
of metastasis. Recently, this has sparked considerable interest in 
the potential modulation of pH in and around tumour cells as a 
novel means of broad-spectrum anti-cancer therapy that may be 
effective regardless of the type of tumour and where it originates. 
Nevertheless, we can conclude that proton flux, largely mediated 
by NHE1 and its interacting partners, promotes carcinogenesis 
and allows cancer cells to thrive in the harsh tumour microenviron-
ment. The role of NHE1 has thus been redefined from a general 
“housekeeping” protein in charge of pH regulation and cell volume 
control, to an essential coordinator of cancer cell development. 
Likewise, its vast potential as a viable chemotherapeutic target, 
whether directly or indirectly in concert with cytotoxic drugs, must 
be reconsidered in our search for a cure.
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